--- title: "18:30 ET\n \n \n SHAREHOLDER ALERT: The M&A Class Action Firm Encourages Stockholders of EMKR, CCRN, WMPN, ALVR to Act Now" type: "News" locale: "en" url: "https://longbridge.com/en/news/228096786.md" description: "Monteverde & Associates PC is urging shareholders of EMCORE Corporation (EMKR), Cross Country Healthcare, Inc. (CCRN), William Penn Bancorporation (WMPN), and AlloVir, Inc. (ALVR) to participate in upcoming shareholder votes regarding proposed mergers. EMKR shareholders will receive $3.10 per share, CCRN shareholders will receive $18.61 in cash, WMPN shareholders will receive shares of Mid Penn, and ALVR will acquire Kalaris Therapeutics. The votes are scheduled for February 27, February 28, April 2, and March 12, 2025, respectively. The firm emphasizes that there is no cost or obligation to shareholders for participation." datetime: "2025-02-12T23:30:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/228096786.md) - [en](https://longbridge.com/en/news/228096786.md) - [zh-HK](https://longbridge.com/zh-HK/news/228096786.md) generator: "portal-rs" --- # 18:30 ET SHAREHOLDER ALERT: The M&A Class Action Firm Encourages Stockholders of EMKR, CCRN, WMPN, ALVR to Act Now , /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a **Top 50 Firm** by ISS Securities Class Action Services Report. We are headquartered at the **Empire State Building** in New York City and are investigating: - **EMCORE Corporation (NASDAQ: EMKR)**, relating to its proposed merger with Velocity One Holdings, LP. Under the terms of the agreement, EMCORE stockholders will receive $3.10 per share of EMCORE common stock they own. **ACT NOW**. The Shareholder Vote is scheduled for **February 27, 2025.** **Click here for more information** https://monteverdelaw.com/case/emcore-corporation-emkr/**.** **It is free and there is no cost or obligation to you.** - **Cross Country Healthcare, Inc. (NASDAQ: CCRN)**, relating to the proposed merger with Aya Healthcare. Under the terms of the agreement, shares of Cross Country will be converted into the right to receive $18.61 in cash. **ACT NOW**. The Shareholder Vote is scheduled for **February 28, 2025.** **Click here for more** https://monteverdelaw.com/case/cross-country-healthcare-inc-ccrn/. **It is free and there is no cost or obligation to you.** - **William Penn Bancorporation (Nasdaq: WMPN),** relating to its proposed merger with Mid Penn Bancorp, Inc. Under the terms of the agreement, shareholders of William Penn will receive 0.4260 shares of Mid Penn common stock for each share of William Penn common stock. Additionally, all options of William Penn will be rolled into Mid Penn equivalent options. The implied transaction value is approximately $13.58 per William Penn share. **ACT NOW**. The Shareholder Vote is scheduled for **April 2, 2025.** **Click here for more information** https://monteverdelaw.com/case/william-penn-bancorporation-wmpn/. **It is free and there is no cost or obligation to you.** - **AlloVir, Inc. (Nasdaq: ALVR)**, relating to its proposed merger with Kalaris Therapeutics. Under the terms of the agreement, AlloVir will acquire 100% of the outstanding equity interest of Kalaris. Upon completion, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company. **ACT NOW**. The Shareholder Vote is scheduled for **March 12, 2025.** **Click here for more information** https://monteverdelaw.com/case/allovir-inc-alvr/. **It is free and there is no cost or obligation to you.** **NOT ALL LAW FIRMS ARE THE SAME.** Before you hire a law firm, you should talk to a lawyer and ask: 1. Do you file class actions and go to Court? 2. When was the last time you recovered money for shareholders? 3. What cases did you recover money in and how much? **About Monteverde & Associates PC** Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. **No company, director or officer is above the law.** If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our **website** or contact Juan Monteverde, Esq. either via e-mail at **\[email protected\]** or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC **The Empire State Building** 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America \[email protected\] Tel: (212) 971-1341 Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde & Associates PC ### Related Stocks - [WMPN.US](https://longbridge.com/en/quote/WMPN.US.md) - [ALVR.US](https://longbridge.com/en/quote/ALVR.US.md) - [KLRS.US](https://longbridge.com/en/quote/KLRS.US.md) - [EMKR.US](https://longbridge.com/en/quote/EMKR.US.md) ## Related News & Research - [Kalaris Therapeutics management to join Morgan Stanley Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297513633.md) - [Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results](https://longbridge.com/en/news/295542706.md) - [Kalaris Therapeutics Q2 net loss narrows on lower administrative costs](https://longbridge.com/en/news/295534891.md) - [Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statement](https://longbridge.com/en/news/294731013.md) - [Kalaris Therapeutics says TH103 Phase 1b/2 trial in neovascular AMD is enrolling patients](https://longbridge.com/en/news/290559679.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**